

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 October 2003 (09.10.2003)

PCT

(10) International Publication Number
WO 03/082241 A2

- (51) International Patent Classification⁷: **A61K 9/00**
- (21) International Application Number: **PCT/IB03/01223**
- (22) International Filing Date: **3 April 2003 (03.04.2003)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
425/DEL/2002 **3 April 2002 (03.04.2002)** **IN**
- (71) Applicant (*for all designated States except US*): **RANBAXY LABORATORIES LIMITED [IN/IN]; 19, Nehru Place, 110 019 New Delhi, Delhi (IN).**
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **RAMPAL, Ashok [IN/IN]; 14, Sewa Nagar, Ram Tirath Road, 143001 Amritsar, Punjab (IN). RAGHUVANSHI, Rajeev, S. [IN/IN]; Flat No. 8131, Block: D-8, Vasant Kunj, 110070 New Delhi, Delhi (IN). PARUTHI, Manoj, Kumar [IN/IN]; c/o Manusthali, H-109 G.F. Residency Greens, Greenwoods City, Gurgaon, 122001 Haryana (IN).**
- (74) Common Representative: **RANBAXY LABORATORIES LIMITED; c/o DESHMUKH, Jay R., 600 College Road East, Suite 2100, Princeton, NJ 08540 (US).**
- (81) Designated States (*national*): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.**
- (84) Designated States (*regional*): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 03/082241 A2

(54) Title: **CLARITHROMYCIN FORMULATIONS HAVING IMPROVED BIOAVAILABILITY**

(57) Abstract: A pharmaceutical composition includes micronized clarithromycin and exhibits improved dissolution characteristics relative to a pharmaceutical composition that includes unmiconized clarithromycin. The clarithromycin may have a particle size less than approximately 35 microns. One process for preparing an extended release tablet of the clarithromycin includes micronizing the clarithromycin; blending the micronized clarithromycin with one or more rate controlling polymers and pharmaceutically acceptable excipients; granulating the blend; and compressing to form a tablet. To treat a bacterial infection in a mammal in need of treatment, a patient may be administered a pharmaceutical composition that includes micronized clarithromycin.

CLARITHROMYCIN FORMULATIONS HAVING IMPROVED BIOAVAILABILITY

TECHNICAL FIELD OF THE INVENTION

- 5 The technical field of the invention relates to solid pharmaceutical compositions of clarithromycin with enhanced absorption and dissolution characteristics provided by micronizing the clarithromycin.

BACKGROUND OF THE INVENTION

- 10 There is an ever-present need in the pharmaceutical industry for improved pharmaceutical formulations that enhance the efficacy of poorly soluble therapeutic agents. There is especially a need for formulations that (1) enhance the absorption of poorly soluble therapeutic agents, and (2) extend the period of duration of effect of the therapeutic agents.

- 15 The aqueous solubility of drug substances plays an important role in the formulation of dosage forms. For the oral route of administration it is well experienced that, unless the substance has an aqueous solubility above 10mg/ml over the pH range 1-7, potential absorption problems may occur. Numerous active ingredients suffer from the disadvantage of being poorly soluble in an aqueous medium, thus having an insufficient dissolution profile and consequently, poor bioavailability following oral administration.
- 20 The therapeutic dose required to be administered must be increased in order to obviate this disadvantage. This necessitates the administration of active ingredients three or four times a day in order to achieve the desired effect.

- 25 For a drug that is administered in multiple doses, it is reported that the patient compliance is as high as 87% when administered once a day as when compared to 39% for a q.i.d. dosage regimen. An extended-release dosage form may improve the quality of therapy and the safety profile relative to a conventional dosage form. However, in order to be effective, these extended release formulations should completely release the drug within a predetermined period.

- 30 Erythromycin and its derivatives are useful in treating bacterial infections and are known as anti-bacterial agents useful against a number of organisms and are typically

administered two to three times a day as immediate release compositions. In particular, 6-O-methoxyerythromycin A (clarithromycin), which has been disclosed in US Patent No. 4,331,803, has to be administered at least twice daily for optimal effect.

SUMMARY OF THE INVENTION

5 In one general aspect, there is provided a pharmaceutical composition which includes micronized clarithromycin and exhibits improved dissolution characteristics relative to a pharmaceutical composition that includes unmicronized clarithromycin.

Embodiments of the pharmaceutical composition may include one or more of the following features. For example, the clarithromycin may have a particle size less than
10 approximately 50 microns, and more particularly, less than 35 microns. The clarithromycin in the pharmaceutical composition may make up between approximately 100 mg and approximately 1000 mg of the pharmaceutical composition. The pharmaceutical formulation may be an extended release formulation.

The pharmaceutical composition may further include one or more rate controlling
15 polymers. The rate controlling polymers may be one or more of carbohydrate gums, polyuronic acid salts, cellulose ethers, and acrylic acid polymers. The carbohydrate gums may be one or more of xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan, and locust bean gum. The polyuronic acid salts may be one or more of alkali metal salts of alginic acid and pectic acid. The cellulose ethers may be one or more of
20 hydroxypropyl methylcellulose, hydroxypropyl cellulose, and carboxymethyl cellulose. The acrylic polymers may be the acrylic polymer available under the brand name carbopol.

The pharmaceutical composition may further include one or more pharmaceutically acceptable excipients. The pharmaceutically acceptable excipients may
25 be one or more of gas generating components, swelling agents, lubricants, and fillers.

The pharmaceutical composition may be a once a day formulation. The dosage form may be a tablet or a capsule.

The clarithromycin may be micronized in air jet mill, and may be co-micronized with one or more pharmaceutical inert carriers. The pharmaceutically inert carrier may be

one or more cellulose derivatives, silicate derivatives, and clays. The cellulose derivative may be one or more of microcrystalline cellulose and carboxymethyl cellulose. The silicate derivative may be one or more of magnesium silicate, colloidal silicon dioxide, magnesium trisilicate, and magnesium aluminicum silicate. The clay may be one or more
5 of veegum and bentonite. The amount of pharmaceutically inert carrier may be between approximately 2% and approximately 25% by weight relative to the total weight of the pharmaceutical composition.

The pharmaceutical composition may exhibit improved absorption characteristics relative to a pharmaceutical composition that includes unmicronized clarithromycin. The
10 pharmaceutical composition has an area-under-the-curve (AUC) comparable to the area-under-the-curve (AUC) of a twice-daily immediate release dosage form.

The pharmaceutical composition may further include one or more of omeprazole, metronidazole, amoxicillin, rifampicin, lansoprazole, ciprofloxacin, ethambutol, and ritonavir. The clarithromycin and the one or more active ingredients may be combined in
15 a single pharmaceutical composition.

The pharmaceutical composition may further include unmicronized clarithromycin, thereby forming a mixture of unmicronized and micronized clarithromycin.

In another general aspect, there is provided a process for preparing an extended release tablet of clarithromycin which includes micronizing clarithromycin; blending the
20 micronized clarithromycin with one or more rate controlling polymers and pharmaceutically acceptable excipients; granulating the blend; and compressing to form a tablet.

Embodiments of the process may include one or more of the following features. For example, the clarithromycin may be micronized to have a particle size less than
25 approximately 50 microns. More particularly, the clarithromycin may be micronized to have a particle size less than 35 microns. The clarithromycin may make up between approximately 100 mg and approximately 1000 mg of the tablet.

In the process, the clarithromycin may be micronized in an air jet mill and micronizing may include co-micronizing the clarithromycin with one or more

pharmaceutical inert carriers. The pharmaceutically inert carrier may be one or more cellulose derivatives, silicate derivatives, and clays.

In another general aspect, there is provided a method of treating a bacterial infection in a mammal in need of treatment which includes administering a pharmaceutical composition comprising micronized clarithromycin and one or more pharmaceutically acceptable excipients.

The clarithromycin in the pharmaceutical composition taken to provide antibacterial activity may include at least some clarithromycin that has been micronized to have a particle size less than 50 microns, and more particularly, less than 35 microns, and the clarithromycin may make up between approximately 100 mg and approximately 1000 mg of the pharmaceutical composition. The method of treating may further include administering one or more of omeprazole, metronidazole, amoxicillin, rifampicin, lansoprazole, ciprofloxacin, ethambutol, and ritonavir with the micronized clarithromycin.

The details of one or more embodiments of the invention are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the description and claims.

DETAILED DESCRIPTION OF THE INVENTION

The process of developing pharmaceutical compositions of clarithromycin is challenging for the pharmaceutical formulator because of opposing solubility and stability constraints. In particular, clarithromycin has increased solubility but reduced stability at the acidic pH conditions in the stomach, and increased stability but reduced solubility at the alkaline pH of the lower portion of the intestine (pH 6.0 to 8.0). These constraints result in poor bioavailability of clarithromycin. In spite of these competing constraints, the inventors nonetheless realized the desirability of dosage forms of clarithromycin having improved dissolution and absorption characteristics that can be administered once per day, and conducted research and development activities for developing such a clarithromycin formulation. As a result of these efforts, the inventors have surprisingly found that the dissolution and absorption characteristics of clarithromycin, as well as its bioavailability, can be increased by micronizing the clarithromycin.

The term "micronization" used herein means any process or methods by which the size of the particles is reduced. As also used herein, clarithromycin particles with reduced size are referred to as "micronized particles of clarithromycin" or "micronized clarithromycin".

5 The clarithromycin used in the pharmaceutical compositions described herein can be prepared by any known method, such as, for example, using either of the procedures disclosed in U.S. Patent No. 4,331,803 or U.S. Patent No. 4,672,109. Both of these patents are incorporated herein in their entirety by reference.

10 The process of the invention for preparing a solid formulation of clarithromycin with improved dissolution and absorption characteristics includes the micronization of clarithromycin. Size reduction, or micronization, may be carried out using any of the conventionally known mills, such as a ball mill, colloid mill, grinding mill, air jet mill, roller mill, impact mill, etc. Air jet milling is particularly well suited for this application as it is a well proven technique that consistently produces particles of a size less than 35
15 microns. Primary advantages of air jet milling are that the predominant particle size reduction occurs through particle to particle collisions, there is limited particle size reduction that results from metal to product contact, and there is no generation of heat that can adversely affect the particles being micronized.

20 The process of air jet milling involves exposing the material to be micronized to streams of compressed air or gas. Particles in the fluidized bed created by the gas streams are accelerated towards the center of the mill and collide with the slower moving particles. These collisions break the particles into smaller particles, thereby micronizing the particles. The air jet mills operate by applying opposing air flows and centrifugal forces. By balancing the two forces, desired particle size and fines can be separated.

25 The reduction of the particle size of clarithromycin to a D_{90} particle size of less than 50 microns, and more particularly less than 35 microns, results in improved bioavailability of clarithromycin pharmaceutical compositions as compared to clarithromycin pharmaceutical compositions that contain larger sized clarithromycin particles. Clarithromycin particles having a D_{90} particle size of less than about 50
30 microns, and more particularly less than about 35 microns, are referred to herein as

“micronized clarithromycin particles.” As used herein, “D₉₀ particle size” is the particle size of at least 90% of the particles of clarithromycin used in the composition.

When clarithromycin is micronized, the resulting particles can be difficult to process because highly micronized particles may possess poor flow properties and have a tendency to agglomerate during processing. To overcome these potential and actual difficulties, the clarithromycin may be micronized in the presence of one or more pharmaceutically inert carrier(s) or mixed with inert carriers after micronization to neutralize the static charge.

As used herein, the term “pharmaceutically inert carrier” refers to a substance that is physiologically acceptable, compatible with the drug and other excipients in the formulation, and has a capacity to adsorb the drug on its surface. Carriers prevent reagglomeration of drug particles and also help in wetting of the drug by uptake of water by capillary action and thereby enhancing drug dissolution further.

The pharmaceutically inert carrier may be selected from cellulose derivatives such as microcrystalline cellulose and carboxymethyl cellulose; silicate derivatives such as magnesium silicate, colloidal silicon dioxide, magnesium trisilicate, and magnesium aluminum silicate; and clays such as veegum, bentonite, etc.

The micronized clarithromycin, micronized either with or without an inert carrier, then is processed to form a solid formulation and finished dosage form (e.g., tablet or capsule) that includes a rate controlling polymer and one or more pharmaceutically acceptable excipients. The rate controlling polymer provides sustained or extended release characteristics to the finished dosage form such that a patient can reduce the number of times per day that they must take clarithromycin to once or twice per day. For example, the amount of micronized clarithromycin in the finished dosage form can be present at between approximately 100 mg and 1000 mg and the finished dosage form taken only once per day. When the clarithromycin is micronized, it exhibits improved dissolution and absorption characteristics relative to marketed clarithromycin formulations.

The rate-controlling polymers of the solid formulation and finished dosage form may be selected from the group that includes carbohydrate gum, polyuronic acid salts, cellulose ethers, acrylic acid polymers and mixtures, thereof. Carbohydrate gums may be

selected from the group that includes xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan, locust bean gum and other carbohydrate gums having similar properties. Polyuronic acid salts include alkali metal salts of alginic acid or pectic acid and mixtures thereof. Examples of alkali metal salts of alginic acid that may be used
5 include sodium alginate, potassium alginate, ammonium alginate and other suitable alkali metal salts of alginic acid. Cellulose ethers include hydroxypropyl methyl cellulose, hydroxypropyl cellulose and other suitable cellulose ethers. Any suitable polyacrylic acid polymer, such as is available under the brand name carbopol, may be used.

The other pharmaceutically acceptable excipients include gas generating
10 components, swelling agents, lubricants, binders, and fillers and diluents. Gas generating components include carbonates, such as calcium carbonate; bicarbonates such as sodium bicarbonate; sulfites such as sodium sulfite; and other suitable known gas generating components. Swelling agents include cross-linked polyvinylpyrrolidone, cross-linked carboxymethyl cellulose sodium, sodium starch glycolate and other suitable, known
15 swelling agents.. Lubricants include talc, calcium stearate, magnesium stearate, polyethylene glycols, silicon dioxide, sodium lauryl sulphate, sodium stearyl fumarate, other suitable, known lubricants, and mixtures thereof. Binders include polyvinyl pyrrolidone (PVP) and other suitable, known binders. Fillers and diluents include lactose and other suitable, known fillers and diluents.

20 The following examples are provided to illustrate various implementations of the invention without being limiting.

EXAMPLE 1**PREPARATION OF EXTENDED RELEASE TABLET FORMULATION OF CLARITHROMYCIN**

Ingredients	Mg/tablet
Clarithromycin micronized (Particle size: D ₉₀ equivalent to 31.93 microns)	1000.0
Hydroxypropyl methylcellulose K15M	10.0
Hydroxypropyl methylcellulose K4M	17.5
Polyvinyl pyrrolidone K-30	25.0
Lactose	50.0
Magnesium stearate	12.5
Talc	10.0
Sodium stearyl fumarate	20.0
Colloidal silicon dioxide	5.0
Total weight	1150.0

5 Micronized clarithromycin, hydroxypropyl methylcellulose K15M, hydroxypropyl methylcellulose K4M, polyvinyl pyrrolidone K30 and lactose were sieved through a British Standard Sieve (BSS) 44 mesh sieve, blended together, and granulated with water. The resulting granulate was dried in a fluid bed drier at 60°C for 20 minutes. The dried granules were sifted through a BSS 16 mesh sieve. The granules obtained were lubricated
10 with the remaining ingredients and compressed to tablets.

 The clarithromycin of the tablet of Example 1 was not micronized with an inert carrier. Nonetheless, a portion of the colloidal silicon dioxide, which is described herein as being a suitable inert carrier for co-micronization, of Example 1 could have been provided for co-micronizing with clarithromycin and the remainder later added for
15 lubrication.

EXAMPLE 2

 Table 1 illustrates the effect of particle size on the in-vitro drug release profile of an extended release clarithromycin tablet. The extended release tablets were prepared according to the composition of Example 1 using two different particle sizes, one
20 micronized (D₉₀=29.73 microns) and another unmicronized (D₉₀=246.39 microns). As

illustrated in Table 1, the micronized clarithromycin formulation provided a significantly improved dissolution profile relative to an unmiconized clarithromycin formulation. The dissolution was carried out in 1000 ml mixed phosphate buffer of pH 4.0, at 80 rpm using USP Apparatus II with 10 mesh sinker basket and the paddle height was adjusted to 4.5 cm from the bottom of the basket.

Table 1

Dissolution profile of clarithromycin extended release pharmaceutical compositions prepared with clarithromycin particles of different sizes carried out in USP apparatus II/1000ml/pH4.0, mixed phosphate buffer/80 rpm.

Time (hr)	Percent (%) drug released	
	Particle size	
	D ₉₀ =29.73 microns	D ₉₀ =246.39 microns
1	14	12
2	30	20
4	59	33
8	99	59
10	103	70

EXAMPLE 3

Bioavailability study: The extended release clarithromycin solid formulation of Example 1 having clarithromycin with a mean particle diameter of 31.93 microns was compared to commercially available tablets (Abbott Laboratories Biaxin film tab 500mg b.i.d.) in a bioavailability study. The bioavailability study was performed on six healthy subjects. It was conducted as a single dose, open, randomized, balanced, crossover study, under fed conditions. Blood samples were drawn at selected times following each treatment. Blood levels of the drug for both the test and the reference drugs were determined and compared for the two critical parameters: Area Under the plasma concentration – time Curve (AUC) and Maximum plasma concentration (C_{max}). The results, shown in Table 2, illustrate the substantially similar bioavailability of an extended release clarithromycin formulation compared to a conventional, twice daily formulation.

Test Drug: Extended release clarithromycin formulation made according to Example 1 and comprising clarithromycin with a particle size of D_{90} equivalent to 31.93 microns.

Reference Drug: Commercially available clarithromycin formulations (Abbott Laboratories, Biaxin Filmtab 500mg) administered twice daily.

5

Table 2

Comparison of bioavailability of extended release micronized clarithromycin formulation and conventional twice daily clarithromycin formulation.

Formulation		AUC 0-24h ($\mu\text{g}\cdot\text{hr}/\text{ml}$)	T/R
Biaxin Filmtab 500mg (R)	b.i.d	37.95	-
	First dose	16.9	-
Clarithromycin XL (T)	1000 mg	36.6	96.4%
	Interpolated value for 500 mg	18.3	108.3%

EXAMPLE 4

10

Example 4 involves preparing an extended release pharmaceutical formulation of clarithromycin that has a mean particle size of D_{90} equivalent to 275.58 microns.

Ingredients	Mg/tablet
Clarithromycin	500
Lactose	117
Hydroxypropyl cellulose-L	105
Hydroxypropyl cellulose – M	125
Polyvinyl pyrrolidone K 30	10
Talc	18
Sodium stearyl fumarate	18
Colloidal silicon dioxide	2
Magnesium stearate	5

Unmicronized clarithromycin, hydroxypropyl cellulose M, hydroxypropyl cellulose L, polyvinyl pyrrolidone K30 and lactose were sieved through a British Standard Sieve (BSS) 44 mesh sieve, blended together, and granulated with water. The resulting

granulate was dried in a fluid bed drier at 60°C for 20 minutes. The dried granules were sifted through a BSS 16 mesh sieve. The granules obtained were lubricated with the remaining ingredients and compressed to form tablets.

The extended release clarithromycin formulation of Example 4 having clarithromycin with a mean particle size of D_{90} equivalent to 275.58 microns was compared to commercially available tablets (Abbott Laboratories Klaricid XL tablets, 500mg) in a bioavailability study. The study was conducted on twelve healthy subjects as single dose, open, randomized, balanced crossover study. The results of the study are presented in Table 3. These results indicate the reduced bioavailability of unmiconized clarithromycin tablets relative to commercially available clarithromycin extended release tablets. The results further support the discovery that micronizing clarithromycin provides improved bioavailability and that to provide the bioavailability of conventional clarithromycin formulations the clarithromycin should be micronized.

Test Drug: Extended release clarithromycin formulation (500 mg) made according to Example 4 and comprising clarithromycin with a particle size of D_{90} equivalent to 275.58 microns.

Reference Drug: Commercially available clarithromycin extended release tablets (Klaricid XL 500 mg)

Table 3

AUC 0-24h ($\mu\text{g}\cdot\text{hr}/\text{ml}$)		T/R
Test	Reference	
13.0	17.72	73.36%

While several particular forms of the invention have been illustrated and described, it will be apparent that various modifications and combinations of the invention detailed in the text can be made without departing from the spirit and scope of the invention. For example, the clarithromycin used in the pharmaceutical compositions does not necessarily need to include only micronized clarithromycin but instead can be made up of a mixture of micronized and unmiconized clarithromycin, e.g., a first batch of clarithromycin is micronized and then mixed with a second batch of clarithromycin which has not been micronized. Moreover, the micronized clarithromycin may be administered with (e.g., as

a single pharmaceutical combination composition, simultaneously, or within a short time) other drugs and drug products to treat conditions that may be related to or that occur concurrently with a condition that involves the treatment of a bacterial infection using clarithromycin. Such drugs that may be co-administered with the micronized

5 clarithromycin generally include one or more of omeprazole, metronidazole, amoxicillin, rifampicin, lansoprazole, ciprofloxacin, ethambutol, and ritonavir. For example, the combinations may include a single pharmaceutical composition or joint administration of:

(1) omeprazole, metronidazole, and clarithromycin; (2) omeprazole, amoxicillin, and clarithromycin; (3) rifampicin and clarithromycin; (4) lansoprazole and clarithromycin; (5)

10 ciprofloxacin and clarithromycin; (6) lansoprazole, amoxicillin, and clarithromycin; and (7) ethambutol, ritonavir, and clarithromycin.

Further, it is contemplated that any single feature or any combination of optional features of the inventive variations described herein may be specifically excluded from the claimed invention and be so described as a negative limitation. Accordingly, it is not

15 intended that the invention be limited, except as by the appended claims.

WE CLAIM:

1. A pharmaceutical composition comprising micronized clarithromycin, wherein the pharmaceutical composition exhibits improved dissolution characteristics relative to a pharmaceutical composition that includes unmiconized clarithromycin.
- 5 2. The pharmaceutical composition of claim 1, wherein the clarithromycin has a particle size less than 50 microns.
3. The pharmaceutical composition of claim 1, wherein the clarithromycin has a particle size less than 35 microns.
- 10 4. The pharmaceutical composition of claim 1, wherein the clarithromycin comprises between approximately 100 mg and approximately 1000 mg.
5. The pharmaceutical composition of claim 1, wherein the pharmaceutical formulation comprises an extended release formulation.
6. The pharmaceutical composition of claim 1, further comprising one or more rate controlling polymers.
- 15 7. The pharmaceutical composition of claim 6, wherein the rate controlling polymers comprises one or more of carbohydrate gums, polyuronic acid salts, cellulose ethers, and acrylic acid polymers.
- 20 8. The pharmaceutical composition of claim 7, wherein the carbohydrate gums comprise one or more of xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan, and locust bean gum.
9. The pharmaceutical composition of claim 7, wherein the polyuronic acid salts comprise one or more of alkali metal salts of alginic acid and pectic acid.
- 25 10. The pharmaceutical composition of claim 7, wherein the cellulose ethers comprise one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, and carboxymethyl cellulose.
11. The pharmaceutical composition of claim 7, wherein the acrylic polymers comprise the acrylic polymer available under the brand name carbopol.

12. The pharmaceutical composition of claim 1, further comprising one or more pharmaceutically acceptable excipients.
13. The pharmaceutical composition of claim 12, wherein the pharmaceutically acceptable excipients comprise one or more of gas generating components, swelling agents, lubricants, and fillers.
14. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises a once a day formulation.
15. The pharmaceutical composition of claim 1, wherein the dosage form comprises a tablet or a capsule.
16. The pharmaceutical composition of claim 1, wherein the clarithromycin is micronized in air jet mill.
17. The pharmaceutical composition of claim 1, wherein the clarithromycin is co-micronized with one or more pharmaceutical inert carriers.
18. The pharmaceutical composition of claim 17, wherein the pharmaceutically inert carrier comprises one or more cellulose derivatives, silicate derivatives, and clays.
19. The pharmaceutical composition of claim 18, wherein the cellulose derivative comprises one or more of microcrystalline cellulose and carboxymethyl cellulose.
20. The pharmaceutical composition of claim 18, wherein the silicate derivative comprises one or more of magnesium silicate, colloidal silicon dioxide, magnesium trisilicate, and magnesium aluminicum silicate.
21. The pharmaceutical composition of claim 18 wherein clay comprises one or more of veegum and bentonite.
22. The pharmaceutical composition of claim 17, wherein the amount of pharmaceutically inert carrier comprises between approximately 2% and approximately 25% by weight relative to the total weight of the pharmaceutical composition.

23. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition exhibits improved absorption characteristics relative to a pharmaceutical composition that includes unmiconized clarithromycin.
- 5 24. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises an area-under-the-curve (AUC) comparable to the area-under-the-curve (AUC) of a twice-daily immediate release dosage form.
- 10 25. The pharmaceutical composition of claim 1, further comprising one or more of active ingredients, wherein the active ingredients comprise one or more of omeprazole, metronidazole, amoxicillin, rifampicin, lansoprazole, ciprofloxacin, ethambutol, and ritonavir.
26. The pharmaceutical composition of claim 25, wherein the clarithromycin and the one or more active ingredients are combined in a single pharmaceutical composition.
- 15 27. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition further comprises unmiconized clarithromycin.
28. A process for preparing an extended release tablet of clarithromycin, the process comprising:
- micronizing clarithromycin;
- 20 blending the micronized clarithromycin with one or more rate controlling polymers and pharmaceutically acceptable excipients;
- granulating the blend; and
- compressing to form a tablet.
29. The process of claim 28, wherein the clarithromycin is micronized to have a particle size less than 50 microns.
- 25 30. The process of claim 28, wherein the clarithromycin is micronized to have a particle size less than 35 microns.

31. The process of claim 28, wherein the clarithromycin comprises between approximately 100 mg and approximately 1000 mg of the tablet.
32. The process of claim 28, wherein micronizing comprises micronizing the clarithromycin in an air jet mill.
- 5 33. The process of claim 28, wherein micronizing comprises co-micronizing the clarithromycin with one or more pharmaceutical inert carriers.
34. The process of claim 33, wherein the pharmaceutically inert carrier comprises one or more cellulose derivatives, silicate derivatives, and clays.
- 10 35. A method of treating a bacterial infection in a mammal in need of treatment, the method comprising administering a pharmaceutical composition comprising micronized clarithromycin and one or more pharmaceutically acceptable excipients.
- 15 36. The method of claim 35, wherein the clarithromycin comprises at least some clarithromycin that has been micronized to have a particle size less than 50 microns.
37. The method of claim 35, wherein the clarithromycin comprises at least some clarithromycin that has been micronized to have a particle size less than 35 microns.
- 20 38. The method of claim 35, wherein the clarithromycin comprises between approximately 100 mg and approximately 1000 mg of the pharmaceutical composition.
39. The method of claim 35, further comprising administering one or more of omeprazole, metronidazole, amoxicillin, rifampicin, lansoprazole, ciprofloxacin, ethambutol, and ritonavir with the micronized clarithromycin.

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
9 October 2003 (09.10.2003)

PCT

(10) International Publication Number
WO 2003/082241 A3

(51) International Patent Classification⁷: **A61K 9/20**, 9/14

(21) International Application Number:
PCT/IB2003/001223

(22) International Filing Date: 3 April 2003 (03.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
425/DEL/2002 3 April 2002 (03.04.2002) IN

(71) Applicant (for all designated States except US): **RANBAXY LABORATORIES LIMITED** [IN/IN]; 19, Nehru Place, 110 019 New Delhi, Delhi (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **RAMPAL**, Ashok [IN/IN]; 14, Sewa Nagar, Ram Tirath Road, 143001 Amritsar, Punjab (IN). **RAGHUVANSHI**, Rajeev, S. [IN/IN]; Flat No. 8131, Block: D-8, Vasant Kunj, 110070 New Delhi, Delhi (IN). **PARUTHI**, Manoj, Kumar [IN/IN]; c/o Manusthali, H-109 G.F. Residency Greens, Greenwoods City, Gurgaon, 122001 Haryana (IN).

(74) Common Representative: **RANBAXY LABORATORIES LIMITED**; c/o DESHMUKH, Jay R., 600 College Road East, Suite 2100, Princeton, NJ 08540 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
8 January 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **CLARITHROMYCIN FORMULATIONS HAVING IMPROVED BIOAVAILABILITY**

(57) Abstract: A pharmaceutical composition includes micronized clarithromycin and exhibits improved dissolution characteristics relative to a pharmaceutical composition that includes unmiconized clarithromycin. The clarithromycin may have a particle size less than approximately 35 microns. One process for preparing an extended release tablet of the clarithromycin includes micronizing the clarithromycin; blending the micronized clarithromycin with one or more rate controlling polymers and pharmaceutically acceptable excipients; granulating the blend; and compressing to form a tablet. To treat a bacterial infection in a mammal in need of treatment, a patient may be administered a pharmaceutical composition that includes micronized clarithromycin.

WO 2003/082241 A3

INTERNATIONAL SEARCH REPORT

PCT/IB 03/01223

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K9/20 A61K9/14		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) WPI Data, EPO-Internal, CHEM ABS Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Week 199720 Derwent Publications Ltd., London, GB; Class A96, AN 1997-221685 XP002254913 & JP 09 067247 A (TAISHO PHARM CO LTD), 11 March 1997 (1997-03-11) abstract	1-3,6,7, 10,12, 13,22, 35-37
X	DATABASE WPI Section Ch, Week 199344 Derwent Publications Ltd., London, GB; Class A96, AN 1993-348367 XP002254914 & JP 05 255120 A (TAISHO PHARM CO LTD), 5 October 1993 (1993-10-05) abstract	1-3,6,7, 10,12, 13,22, 35-37
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *Z* document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
22 September 2003		13/11/2003
Name and mailing address of the ISA European Patent Office, P.B. 5618 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Rankin, R

INTERNATIONAL SEARCH REPORT

PCT/IB 03/01223

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	RASENACK N ET AL: "MIKRO- UND NANOTEILCHEN DIE BEDEUTUNG DER TEILCHENGROESSE IN DER PHARMAZIE" PZ PRISMA, VI VERLAG, ESCHBORN,, GO, vol. 9, no. 3, 2002, pages 183-190, XP008021338 ISSN: 0945-5566 page 183 -page 190 ---	1-39
Y	WO 00 48607 A (LEK TOVARNA FARMACEVTSKIH ;MOHAR MILOJKA (SI); REBI & CCARON (SI);) 24 August 2000 (2000-08-24) page 1, line 13 -page 2, line 7 examples ---	1-39
Y	WO 02 17885 A (KUMAR MANOJ ;RAMPAL ASHOK (IN); RANBAXY LAB LTD (IN); RAGHUVANSHI) 7 March 2002 (2002-03-07) page 1, line 1 - line 8 page 2, line 9 - line 12 examples -----	1-39

INTERNATIONAL SEARCH REPORT

PCT/IB 03/01223

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 35-39
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 35-39 are directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the composition.

Continuation of Box I.1

Claims Nos.: 35-39

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

INTERNATIONAL SEARCH REPORT

PCT/IB 03/01223

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
JP 9067247	A	11-03-1997	NONE		
JP 5255120	A	05-10-1993	NONE		
WO 0048607	A	24-08-2000	SI	20150 A	31-08-2000
			AU	2704900 A	04-09-2000
			BG	105914 A	31-05-2002
			CZ	20012964 A3	16-01-2002
			EE	200100433 A	16-12-2002
			EP	1150686 A1	07-11-2001
			HR	20010684 A1	31-10-2002
			HU	0105481 A2	29-05-2002
			PL	350419 A1	16-12-2002
			WO	0048607 A1	24-08-2000
			SK	11972001 A3	05-02-2002
			TR	200102396 T2	21-01-2002
WO 0217885	A	07-03-2002	AU	8432401 A	13-03-2002
			EP	1315478 A2	04-06-2003
			WO	0217885 A2	07-03-2002
			US	2002081332 A1	27-06-2002

